3.80
-0.60 (-13.64%)
Previous Close | 4.40 |
Open | 4.55 |
Volume | 132,868 |
Avg. Volume (3M) | 44,282 |
Market Cap | 140,660,416 |
Price / Earnings (TTM) | 7.76 |
Price / Sales | 4.48 |
Price / Book | 6.05 |
52 Weeks Range | |
Earnings Date | 15 May 2025 |
Profit Margin | 33.62% |
Operating Margin (TTM) | 42.79% |
Diluted EPS (TTM) | 0.490 |
Quarterly Revenue Growth (YOY) | 20.00% |
Quarterly Earnings Growth (YOY) | -1.10% |
Total Debt/Equity (MRQ) | 52.51% |
Current Ratio (MRQ) | 1.77 |
Operating Cash Flow (TTM) | -6.31 M |
Levered Free Cash Flow (TTM) | -4.00 M |
Return on Assets (TTM) | 14.21% |
Return on Equity (TTM) | 33.39% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Bearish | Bearish |
Medical Devices (Global) | Bearish | Bearish | |
Stock | Baird Medical Investment Holdin | - | - |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 5.0 |
Technical Oscillators | 2.0 |
Average | 0.75 |
Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods. |
|
Sector | Healthcare |
Industry | Medical Devices |
% Held by Insiders | 99.92% |
% Held by Institutions | 1.40% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
19 May 2025 | Announcement | Baird Medical Engages Global Clinical Leaders at AAES 2025 |
12 May 2025 | Announcement | Baird Medical Advances Thyroid MWA Training and Academic Exchange with Leading Harvard Professor |
06 May 2025 | Announcement | Baird Medical to Participate in the AAES 2025 Annual Meeting |
05 May 2025 | Announcement | Baird Medical to Participate in COSM 2025 Conference |
28 Apr 2025 | Announcement | Baird Medical Hosts Advanced Microwave Ablation Training with Top Thyroid Specialists |
24 Apr 2025 | Announcement | Baird Medical Hosts Malaysian Thyroid Specialists for Advanced Microwave Ablation Training in China |
14 Apr 2025 | Announcement | Baird Medical Presents Advanced MWA Technology to UCLA Expert in China |
09 Apr 2025 | Announcement | Baird Medical Advances Global Expansion of Microwave Ablation Technology |
02 Apr 2025 | Announcement | Baird Medical Showcases Advanced MWA Technology with UCSF Expert in Guangzhou and Shenzhen |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |